X4 Pharmaceuticals Cuts Costs, Drives 176-Patient Phase 3 for Chronic Neutropenia
X4 Pharmaceuticals has cut costs and headcount since last August to focus on its 176-patient Phase 3 4WARD trial for chronic neutropenia, aiming to complete enrollment by Q3 2026. The company has deprioritized WHIM commercialization despite FDA approval and projects an initial addressable chronic neutropenia base case of 5,000 patients.
1. Strategic Refocus and Cost Reductions
Since August, new leadership has trimmed headcount and slashed operating expenses after recognizing that commercial spending on WHIM syndrome exceeded revenue. While mavorixafor remains available for existing WHIM patients, active promotion has been halted to reallocate resources toward the chronic neutropenia program.
2. Phase 3 4WARD Trial Design
The 4WARD trial will enroll 176 chronic neutropenia patients randomized 1:1 to oral mavorixafor versus placebo with optional G-CSF background therapy. Eligible patients must have experienced at least two infections in the past year, and the co-primary endpoints are absolute neutrophil count increases and infection reduction, with enrollment targeted by Q3 2026.
3. Market Opportunity and Competitive Landscape
Market research estimates roughly 15,000 symptomatic chronic neutropenia patients, with X4’s base case treating about 5,000 initially. The company highlights oral mavorixafor’s advantages over subcutaneous G-CSF—used by about 40% of patients—and sees limited competition from IV plerixafor, which has minimal chronic neutropenia data.
4. Upcoming Milestones and Safety Updates
Key upcoming milestones include an enrollment update, a proposed G-CSF titration study design, and a pricing strategy presentation. An independent data monitoring committee has raised no safety concerns, though gastrointestinal toxicity may require symptomatic management.